Skip to main content
Medic Debate
- The Antidote to Medical Misinformation and Propaganda!
Languages
Dansk
Nederlands
English
Français
Deutsch
Italiano
Español
Kiswahili
Svenska
Search form
Search
Main menu
Home
Search
About us
Books
Category Search
Log In
Recent posts
Treatment Protocols
You are here
Home
Bevacizumab
Items per page
5
10
20
40
60
100
Title
Average Rating
Anti-angiogenic therapies for metastatic colorectal cancer.
60.00%
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
80.00%
Lessons learned in the development of targeted therapy for malignant gliomas
50.00%
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplat
40.00%
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer.
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).
70.00%
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
80.00%
Bevacizumab for recurrent ependymoma.
80.00%
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal
50.00%
Chemoradiotherapy in malignant glioma: standard of care and future directions.
50.00%
Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab....
40.00%
Complete remission of psoriasis following bevacizumab therapy for colon cancer.
60.00%
Dose-Dense and/or Metronomic Schedules of Specific Chemotherapies Consolidate the Chemosensitivity of Triple-Negative Breast Can
63.33%
Hypoxia-inducible factor-1alpha modulation in combination with anti-angiogenic therapy.
60.00%
Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs.
90.00%
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symp
60.00%
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients ....
80.00%
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
80.00%
Novel anti-angiogenic therapies for malignant gliomas.
50.00%
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.
50.00%
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer.
50.00%
Tumoral angiogenesis: review of the literature.
50.00%